Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Fiche publication
Date publication
août 2018
Journal
Heart (British Cardiac Society)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Rossignol P, Pizard A, Machu JL, Collier T, Girerd N, Huby AC, Gonzalez A, Diez J, López B, Sattar N, Cleland JG, Sever PS, Zannad F
Lien Pubmed
Résumé
An increase in myocardial collagen content may contribute to the development of heart failure; this might be inhibited or reversed by mineralocorticoid receptor antagonists (MRAs). We investigated changes in serum concentrations of the collagen synthesis biomarkers N-terminal propeptide of procollagen type III (PIIINP) (primary outcome) and C-terminal propeptide of procollagen type I (PICP) (secondary outcome) after non-randomised initiation of spironolactone as add-on therapy among patients with resistant hypertension enrolled in the 'Anglo-Scandinavian Cardiac Outcomes' trial (ASCOT).
Mots clés
heart failure, hypertension
Référence
Heart. 2018 Aug 18;: